ArticleAsia-Pacific journal of clinical oncology2025
Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing?
Article in Asia-Pacific journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing?Asia-Pacific journal of clinical oncology · 2025Article
- What Is the Evidence Base Regarding Early Onset Colorectal Cancer in Australia and New Zealand? A Scoping Review.ANZ journal of surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe incidence of certain cancers in those under 50 years old (early-onset cancers) has been rising in many countries. This increase is generally unexplained and has significant implications for health policies and treatment. We wish to understand if this trend is occurring in Aotearoa New Zealand and whether it is across the spectrum of adenocarcinomas or site (cancer location)-specific. Differences in patterns between sites would suggest different possible etiologies for any increase in incidence and hence differences in how this trend might be managed.
methodThe change in incidence of esophageal, gastric, colorectal, pancreatic, breast, lung, uterine, ovarian, and prostate adenocarcinomas from 2000 to 2020 in Aotearoa New Zealand was analyzed. Data was extracted from the New Zealand Cancer Registry. All new cases of relevant adenocarcinomas were analyzed to calculate the crude incidence, incidence rate ratios (IRRs), and age-standardized incidence. Trends were estimated by age and ethnicity, focusing on early-onset adenocarcinomas.
resultsThere was evidence for increases in early-onset colorectal (IRR 1.23, p < 0.01), breast (IRR 1.08, p < 0.01), uterine (IRR 1.73, p < 0.01), and prostate adenocarcinomas (IRR 1.14, p < 0.05). In Māori, there was evidence for significant increases in colorectal (IRR 1.42, p < 0.01), uterine (IRR 1.98, p < 0.01), and lung adenocarcinomas (IRR 1.23, p < 0.05).
conclusionFrom 2000 to 2020, there were increases in multiple early-onset adenocarcinomas. This is site-specific, namely colorectal, breast, uterine, and prostate. Ongoing research is needed to investigate possible causes and develop strategies to address the increase in site-specific early-onset adenocarcinoma incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.